TY  - JOUR

T1  - DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

JO  - Journal of Clinical Oncology

PY  - 2022/02/20

AU  - McBride SM

AU  - Niazi T

AU  - Williams S

AU  - Davis ID

AU  - Stockler MR

AU  - Martin AJ

AU  - Bracken K

AU  - Roncolato FT

AU  - Horvath L

AU  - Sengupta S

AU  - Martin J et al

ED  - 

DO  - DOI: 10.1200/jco.2022.40.6_suppl.tps284

PB  - American Society of Clinical Oncology (ASCO)

VL  - 40

IS  - 6_suppl

SP  - TPS284

EP  - TPS284

Y2  - 2024/12/29

ER  -